Elevating laboratory efficiency and patient care QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho") announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310329666/en/QuidelOrtho® Results Manager™ System (Graphic: Business Wire) The QuidelOrtho Results Manage

QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025. Members of QuidelOrtho's management team will participate in a presentation at 8:40 a.m. ET / 5:40 a.m. PT. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com. About QuidelOrtho Corporation QuidelOr

Strong finish to 2024 with continued progress in cost-savings initiatives to drive adjusted EBITDA margin expansion in 2025 and beyond Company issues full-year 2025 financial guidance Fourth Quarter and Full-Year 2024 Results (all comparisons are to the prior year period) Fourth quarter 2024 revenue was $708 million, as reported Non-respiratory revenue was $565 million, which was flat compared to the prior year period due to a decline in U.S. Donor Screening revenue, a business the Company is exiting; Labs revenue grew 4%, as reported and in constant currency, excluding COVID-19 and non-core revenues1 Respiratory revenue was $143 million, a decrease of 18%, as reported and in co

Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously

Jefferies initiated coverage of QuidelOrtho with a rating of Hold and set a new price target of $43.00

UBS resumed coverage of QuidelOrtho with a rating of Neutral and set a new price target of $50.00 from $42.00 previously

4 - QuidelOrtho Corp (0001906324) (Issuer)

4 - QuidelOrtho Corp (0001906324) (Issuer)

4 - QuidelOrtho Corp (0001906324) (Issuer)

4 - QuidelOrtho Corp (0001906324) (Issuer)

4 - QuidelOrtho Corp (0001906324) (Issuer)

8-K - QuidelOrtho Corp (0001906324) (Filer)

10-K - QuidelOrtho Corp (0001906324) (Filer)

SCHEDULE 13G/A - QuidelOrtho Corp (0001906324) (Subject)

Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi

QuidelOrtho Corporation (NASDAQ:QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910545042/en/Lee Bowman, Chief Human Resources Officer, QuidelOrtho (Photo: Business Wire) Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries.

Strong finish to 2024 with continued progress in cost-savings initiatives to drive adjusted EBITDA margin expansion in 2025 and beyond Company issues full-year 2025 financial guidance Fourth Quarter and Full-Year 2024 Results (all comparisons are to the prior year period) Fourth quarter 2024 revenue was $708 million, as reported Non-respiratory revenue was $565 million, which was flat compared to the prior year period due to a decline in U.S. Donor Screening revenue, a business the Company is exiting; Labs revenue grew 4%, as reported and in constant currency, excluding COVID-19 and non-core revenues1 Respiratory revenue was $143 million, a decrease of 18%, as reported and in co

Top-line Results In Line with Expectations; Company Expects to Report Fourth Quarter and Full Year 2024 Financial Results on February 12, 2025 QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced preliminary unaudited revenue for the fourth quarter ended December 29, 2024. Fourth Quarter 2024 Preliminary Unaudited Revenues The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately $702 million to $707 million, which would be in line with its previously announc

― Company reinstates 2024 financial guidance ― ― Drives cost-savings and growth initiatives ― ― Strengthens leadership team and aligns organization for improved effectiveness ― Third Quarter 2024 Results and Recent Developments (all comparisons are to the prior year period) Reported revenue was $727 million Recurring revenue1 was $598 million as reported with no significant change in constant currency, excluding COVID-19 and U.S. Donor Screening revenue Labs revenue grew 4% as reported and 5% in constant currency GAAP operating expenses2 of $242 million decreased by $13 million; non-GAAP operating expenses of $232 million decreased by $17 million, reflecting ongoing implementa

SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)